Mar 6 2010
Global Medical Products Holdings, Inc. (GMDP; http://www.globalmedicalcorporation.com) retained the Mina Mar Group Inc. (http://www.minamargroup.com/) as the lead merger representative for the company' expansive corporate interests.
Mina Mar Group will lead the company as its head Merger Corporate Advisor and its affiliate company Mina Mar Marketing Group www.minamargroup.net will take over the Investor Relations (IR) tasks. The mandate is to represent GMDP' interests in public market, bringing the company closer to the investors' community.
A source close to the company, said, "We remind our followers that GMDP is a company operating under the auspices of the court appointed guardian - custodian. We have posted a number of pdf documents on our corporate web site, http://www.globalmedicalcorporation.com and our IR web site "CLIENT SUPPORT" section. We ask our followers to review these documents, and in particular the document named General Company update dated March 3. This document is self explanatory.
In preparation for the merger the company recently recapitalized its Authorized Share Structure to 2,000 Million Shares.
The only currency the company has, are its restricted shares, and cash in a form of a loan or financing from its preferred shareholders or accredited investors. Usual process in the merger is that a company will need to be recapitalized to absorb the merger, and pay for the assets being acquired. Depending on the situation, sometimes both cash and shares are issued in the merger. Obviously, the higher the share price of our stock the less stock the company has to issue in the merger to the targeted merger company.
This merger is being created whereby these shares will be held in escrow upon the merger and remain the control block for some time after the merger. The float and the free trading shares usually remains undisturbed after the merger. The shares these companies receive are subject to insiders and control block and referred to as Rule 144 stock, and are restricted shares; meaning they cannot trade; henceforth as aforementioned the float remains undisturbed after the merger.
The company will shortly begin updating Pink Sheets with Adequate Disclosure, Updated Financials and report all relevant merger news. There is no reverse split, nor any toxic financing planned for the company. The company has made available sufficient funds and resources through its preferred shareholders and accredited investors to become a vibrant and operational company.
On that note, on February 25 the company posted possible China merger candidates on its web site. This is a preliminary list. Our merger representative operates a back office for Directors and Officers of public companies who can log in and view and begin discussions with suitable candidates. So far GMDP is in discussions with a China based animal medical manufacturing company servicing this growing and expanding industry. Revenues and assets are in the 4 to 5 $ million dollar range.
Immediate plans include representatives and CEO' from the targeted merger companies will find their way to the Mina Mar Group Shareholders' Conference on April 9, in Toronto where GMDP will be greeting its own shareholders and guests; for further discussions and a possible finalization of the merger transaction shortly thereafter. Again, merger transactions are a process and subject to change.
Source:
Global Medical Products Holdings, Inc.